A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Leukemia
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 1 years and 21 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02723994
- Collaborators
- Children's Oncology Group
- Investigators
- Study Director: Albert Assad, MD Incyte Corporation Study Chair: Sarah Tasian, MD Children's Hospital of Philadelphia, Philadelphia, PA Study Chair: Mignon Loh, MD UCSF Benioff Children's Hospital, San Francisco, CA
Get Well Soon